SCHEMBL4351655

SCHEMBL4351655

COc1ccc(C=C2SC(N3CCOCC3)=NC2=O)cc1OC

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.80
KMT2A Q03164 8/20 0.80
MCHR1 Q99705 1/20 0.78
MAPT P10636 4/20 0.67
POLB P06746 2/20 0.67
HPGD P15428 2/20 0.67
GAA P10253 2/20 0.62
GFER P55789 1/20 0.62
RAB9A P51151 2/20 0.57
NPC1 O15118 1/20 0.57
GRIN1 Q05586 1/20 0.56
GRIN2B Q13224 1/20 0.56
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C19 P33261 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351654 1.00 MEN1 (0.80) MEN1KMT2AMCHR1MAPTPOLB
SCHEMBL823133 0.92 MCHR1 (0.91) MEN1KMT2AMCHR1MAPTPOLB
SCHEMBL4348827 0.90 MEN1 (0.76) MEN1KMT2AMCHR1MAPTPOLB
SCHEMBL4348830 0.90 MEN1 (0.76) MEN1KMT2AMCHR1MAPTPOLB
SCHEMBL4350528 0.90 MEN1 (0.66) MEN1KMT2AMCHR1MAPTPOLB
SCHEMBL4350531 0.90 MEN1 (0.66) MEN1KMT2AMCHR1MAPTPOLB
SCHEMBL4364812 0.88 MEN1 (0.62) MEN1KMT2AMCHR1MAPTPOLB
SCHEMBL4350796 0.88 MEN1 (0.62) MEN1KMT2AMCHR1MAPTPOLB
SCHEMBL4350802 0.88 MEN1 (0.62) MEN1KMT2AMCHR1MAPTPOLB
SCHEMBL4356173 0.88 MEN1 (0.62) MEN1KMT2AMCHR1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MEN1 1725/4885KMT2A 3923/4885MCHR1 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.